Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis

被引:9
|
作者
Sozeri, Betul [1 ]
Kasapcopur, Ozgur [2 ]
机构
[1] Ege Univ, Fac Med, Dept Pediat, Izmir, Turkey
[2] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat, Istanbul, Turkey
关键词
Colchicine resistance; Familial Mediterranean fever; therapy; SUBCLINICAL INFLAMMATION; PERIODIC SYNDROME; INTERFERON-ALPHA; TURKISH PATIENTS; DOUBLE-BLIND; CANAKINUMAB; ARTHRITIS; EFFICACY; PROTEIN; TRIAL;
D O I
10.2174/0929867322666150311152300
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory syndrome. FMF is caused by mutations in the MEFV gene which encodes the pyrin protein. FMF is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1-3 days. Patients may develop renal amyloidosis. Colchicine prevents attacks and renal amyloidosis. 5% to 10% of the patients with FMF are resistant or intolerant to colchicine. Colchicine resistant patients may receive biological therapies. Anti-interleukin-1 drugs are the most important agents of biological treatments. In this review, colchicine resistance and treatment options will be evaluated.
引用
收藏
页码:1986 / 1991
页数:6
相关论文
共 50 条
  • [31] Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
    Georges El Hasbani
    Ali Jawad
    Imad Uthman
    Orphanet Journal of Rare Diseases, 14
  • [32] Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever
    Tekgoz, Emre
    Colak, Seda
    Cinar, Fatma Ilknur
    Yilmaz, Sedat
    Cinar, Muhammet
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (05) : 2357 - 2363
  • [33] Colchicine Failure in Familial Mediterranean Fever and Potential Alternatives: Embarking on the Anakinra Trial
    Ben-Zvi, Ilan
    Livneh, Avi
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (05): : 271 - 273
  • [34] Canakinumab Treatment in Familial Mediterranean Fever Patients: With/Without Colchicine
    Ogut, Tahir Saygin
    Yazisiz, Veli
    Dilbil, Melis
    Nokay, Mine
    Terzioglu, Mustafa Ender
    Erbasan, Funda
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2025, 28 (03)
  • [35] Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever
    Laskari, Katerina
    Boura, Panagiota
    Dalekos, George N.
    Garyfallos, Alexandros
    Karokis, Dimitrios
    Pikazis, Dimitrios
    Settas, Loukas
    Skarantavos, Grigoris
    Tsitsami, Elena
    Sfikakis, Petros P.
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (01) : 102 - 109
  • [36] Factors Associated With Successful Withdrawal of Biologic Agents in Children With Colchicine-Resistant Familial Mediterranean Fever
    Tas, Ozen
    Aydin, Fatma
    Sezer, Muge
    Acar, Banu Celikel
    Bahceci, Onur
    Cakar, Nilgun
    Dumlupinar, Ebru
    Ozcakar, Zeynep Birsin
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2024, 30 (07) : 257 - 263
  • [37] Emergence of colchicine resistance in pediatric familial Mediterranean fever: A harbinger of severe enterocolitis
    Stephenson, Aidan Michael
    Chow, Jacky
    Seth, Sanjay
    Miettunen, Paivi
    CRITICAL PUBLIC HEALTH, 2024, 34 (01) : 132 - 133
  • [38] Is compressed colchicine tablet superior to other colchicine preparations in patients with familial Mediterranean fever?
    Vasi, Ibrahim
    Kardas, Riza Can
    Yildirim, Derya
    Kaya, Burcugul
    Duran, Rahime
    Karadeniz, Hazan
    Guler, Aslihan Avanoglu
    Erden, Abdulsamet
    Kucuk, Hamit
    Goker, Berna
    Tufan, Abdurrahman
    Ozturk, Mehmet Akif
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (02) : 77 - 82
  • [39] Amyloidosis of familial Mediterranean fever and the MEFV gene
    Pras, M
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2000, 7 (04): : 289 - 293
  • [40] The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
    Betul Sozeri
    Nesrin Gulez
    Malik Ergin
    Erkin Serdaroglu
    Molecular and Cellular Pediatrics, 3 (1)